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Abstract
Background: The incidence of pertussis has been increasing worldwide. In the Netherlands, the seroprevalence has
risen higher than the reported cases, suggesting that laboratory tests for pertussis are considered infrequently and
that even more pertussis cases are missed. The objective of our study was to determine the frequency of pertussis
in clinically unsuspect cases compared to suspect cases with the intention of finding clinical predictors.
Methods: The present prospective cohort study was part of a controlled clinical trial evaluating the impact of
molecular diagnostics on clinical decision making in pediatric respiratory infections, performed during 2 winter
seasons. For this study, in the first season pertussis was only tested in case of clinical suspicion, in the second
season, pertussis was also tested without clinical suspicion. Multivariate and univariate analysis were performed
using SPSS 18 and Statistical software ‘R’.
Results: In the two seasons respectively 22/209 (10,5%) and 49/373 (13,1%) cases were clinically suspected of
pertussis. Bordetella pertussis was detected by real time RT-PCR in respectively 2/22 (9,1%) and 7/49 (14,3%) cases.
In the second season an additional 7 cases of pertussis were found in clinically unsuspected cases (7/257 = 2,7%).
These additional cases didn’t differ in clinical presentation from children without a positive test for pertussis with
respect to respiratory symptoms.
Conclusions: Pertussis in children sometimes mimics viral respiratory tract infections. If pertussis diagnostics are
based on clinical suspicion alone, about 1 in 5 cases (19%) is missed. Despite widely accepted clinical criteria,
paroxysmal cough is not a good predictor of pertussis. To prevent spreading, physicians should include
B. pertussis in routine diagnostics in respiratory tract infections.
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Background
Currently, an increase in reported cases of pertussis is
noted in many countries, even in countries with high vac-
cination coverage [1,2]. However, a higher rise in sero-
prevalence is observed in relation to reported cases [3].
From this study one may conclude that cases of pertussis
are missed. A possible explanation for this is the wide clin-
ical spectrum of pertussis, ranging from a classical presen-
tation with severe disease and paroxysmal cough to mild
disease with only rhinitis. Life threatening disease with
apneas is usually restricted to young infants that have not
been (fully) immunized. The classic presentation of per-
tussis is well-known, but is observed less often since start
of immunization. Not only immunization, but also previ-
ous infection may lead to atypical (mild) pertussis disease
which is often not recognized [2,4,5]. These atypical cases
are held responsible for ongoing transmission within the
population [4,6].
Respiratory (co-) infections may complicate a correct
clinical diagnosis of B. pertussis infection. Several studies
show that clinical presentation of pertussis is indistin-
guishable from viral respiratory infections and that co-
infection with pertussis exists [4,7-9]. Considering the
heterogenic clinical picture of B. pertussis infections, the
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diagnosis cannot solely be made on clinical criteria. Des-
pite this, not all countries apply laboratory tests but rely
on WHO case definitions of pertussis [10]. To control
the spread of pertussis within the general population
more frequent laboratory confirmation should be advo-
cated [7,11].
Since pertussis may mimic a viral respiratory infection
and present without classic symptoms, cases of pertussis
are probably not recognized. The frequency of missed
diagnosis is not known. Therefore, we conducted a study
during two winter seasons in pediatric patients present-
ing with an acute respiratory tract infection (ARI). We
assessed the frequency of pertussis in clinical suspected
and unsuspected cases. Our primary goal was to deter-
mine the frequency of B. pertussis cases in the group of
unsuspected children in relation to the group of clinic-
ally suspected children and to determine clinical predic-
tors of B. pertussis infection in young children.
Methods
Study design
This prospective cohort study originated in the EVIDENCE-
trial (Evaluation of Viral Diagnostics on Respiratory Infec-
tions in Children) which was designed as a multicenter,
controlled, clinical trial to evaluate the impact of real-time
reversed transcriptase polymerase chain reaction (RT-
PCR) diagnostics in pediatric patients with ARI. ARI was
defined as a new episode of respiratory symptoms of the
upper and/or lower airways. The study protocol and defi-
nitions has been described before and will be summarized
below [12]. The trial was conducted during 2 consecutive
winter seasons (November 2007-May 2009) at the Rein-
ier de Graaf Hospital, Delft, which was joined in the sec-
ond season by the Groene Hart Ziekenhuis, Gouda, the
Netherlands. Both serve as university teaching hospitals.
For this prospective cohort study of pediatric pertus-
sis infections, specimens for pathogen diagnosis (mostly
nasal wash specimens/nasopharyngeal aspirates (NWSs)
or sometimes throat swabs) were collected from all chil-
dren < 12 years of age with suspected ARIs who were
referred to the pediatrician. All patients, or their legal
representatives, gave informed consent. Clinical man-
agement was based on pediatric history and physical
examination. The pediatrician decided whether to per-
form pertussis diagnostics on the basis of the WHO def-
inition of pertussis. However, due to some subjective
criteria in this definition, the interpretation of the cri-
teria might be different between doctors. Therefore,
strict indications for performing pertussis diagnostics
were not defined in this study. The method used for de-
tection of B. pertussis in these specimens was an RT-
PCR targeting IS481.
In the first winter season laboratory confirmation of B.
pertussis infection was only performed in case of clinical
suspicion of pertussis. In the second season laboratory
testing was performed in all cases with or without clin-
ical suspicion. In cases without clinical suspicion diag-
nostics was performed retrospectively on NSWs that
were still available. Unfortunately, it was not possible to
perform retrospective analysis on the samples of unsus-
picious cases in the first winter season because those
samples were not preserved (see Figure 1). Four groups
were formed: 1.Clinical suspicion RT-PCR pertussis posi-
tive (Figure 1, group A and C); 2. Clinical suspicion RT-
PCR pertussis negative (Figure 1, group B and D); 3. Non
suspicion RT-PCR pertussis positive (Figure 1, group E)
and 4. Non suspicion RT-PCR pertussis negative (Figure 1,
group F).
Details about in- and exclusion criteria, definitions
of upper (URTI) en lower respiratory tract infections
(LRTI), data collection and sample processing have been
published before [12]. Clinical data were prospectively
collected for each patient by using a case report form by
the clinician and missing data and laboratory parameters
were retrieved from the electronical medical and hos-
pital records. Variables used for analysis include: age,
gender, fever, paroxysmal cough, rhinorrhea, wheezing,
apneas, nasogastric feeding, days of illness, disease sever-
ity score, hospitalization and days in hospital, antibiotic
therapy, location of infection (URTI, LRTI), diagnostic
methods and presence of co-infections.
The disease severity score used in this study is a modifi-
cation of the severity score developed by Gern [13]. In our
modified score, fever, cough, rhinorrhea and duration of
illness >4 days count 1 point each. Apnea counts 3 points.
Wheezing, cyanosis, retractions and tachypnea count 5
points each. The maximum score is 27.
Statistical analysis
Demographic characteristics were extracted and fre-
quencies were calculated using SPSS 18 (SPSS, Chicago,
IL). The following three intimately linked analyses have
been performed with the aim to find discriminative pa-
rameters for pertussis:
In the first analysis we attempted to uncover discrimina-
tive parameters for clinical suspicion of pertussis by com-
paring clinical suspicious RT-PCR-positive cases (group A
and C, n = 9) versus clinical suspicious PCR-negative cases
(group B and D, n = 62) (analysis took place on both winter
seasons). In the second analysis (restricted to the second
season) we tested which clinical parameters distinguished
clinical suspected pertussis cases (group C, n = 7) from
non-suspected pertussis cases (group E, n = 7) cases. In the
third analysis (restricted to the second season): all RT-
PCR-positive samples (group C and E, n = 14) were com-
pared to all RT-PCR negative samples (group D and F, n =
292) to further analyze predictive clinical parameters.
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To test differences in (multiple) clinical parameters of
two groups multivariate analysis were performed using
a non-parametric test called Permanova (for details see
Appendix) [14]. If the multivariate analysis showed signifi-
cant differences between the groups tested, post-hoc uni-
variate analyses were performed using a Kruskall Wallis
and binomial tests (details see Appendix) to see which pa-
rameters contributed to this difference. The false discovery
ratio was used to control for the family wise error rate
[15]. To visualize the (multidimensional) differences be-
tween the groups, a non-metric dimensional scaling
(NMDS) was applied, which displays the patients accord-
ing to their similarity to each other [16] (for details see
Appendix). Analysis were performed using the statistical
software ‘R’ (R Development Core Team [17]). Significance
was determined at a level of α < 0.05.
Figure 1 Flowchart of patient enrollment.
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Medical ethical approvement
The Evaluation of Viral Diagnostics on Respiratory In-
fections in Children trial protocol was approved by the
regional medical ethics committee and The Central Com-
mittee on Research Involving Human Subjects (known by its
Dutch initials, CCMO, Centrale Commissie Mensgebonden
Onderzoek) number NL13839.098.06.
Results
Patient enrollment
In total, 776 NWSs were analyzed. We excluded 163 be-
cause they were obtained from children who did not meet
inclusion criteria for various reasons (see Figure 1). Of the
613 samples who did met the inclusion criteria, we ex-
cluded another 31 samples because the clinical data were
incomplete. Of the remaining 582 NWSs (from 542 pa-
tients), 209 were included in the first season and 373 cases
in the second season. Both seasons included in our study
were seasons with high incidence of pertussis in the
Netherlands (40–50 cases per 100.000) [18].
Seventy-one samples were taken from children with
clinical suspicion for pertussis (1st season n = 22/2nd sea-
son n = 49). PCR analysis on pertussis was performed on
these samples prospectively. In the second season 324
samples from non-suspicious children were retrospectively
analyzed. Unfortunately, of 67 samples (out of 324 NWSs)
too little material was left for RT-PCR after thawing, leav-
ing 257 samples for retrospective analysis. A summary of
in- and exclusion numbers is given in Figure 1. Mean age
was 8,2 months (median 4.2) and 57,7% was male. URTI
was diagnosed in 324/582 (55,7%) children. Exclusively
LRTI in 2/582 (0,3%) and combined infections in 232/582
(39,9%) children. Paroxysmal cough was found in 97/582
(16,7%) children and 434/582 (74,6%) were admitted to
the pediatric ward.
Outcomes
Table 1 shows the number of pertussis cases diagnosed in
each of the two seasons. In the first winter season clinical
suspicion of pertussis was raised in 22 cases (group A and B)
out of 209 (10,5%), two cases of pertussis were diagnosed
by RT-PCR (2/22 = 9,1%). In the second winter season
clinical suspicion of pertussis was raised in 49 cases (group
C and D) out of 373 (13,1%), seven cases of pertussis were
diagnosed by RT-PCR (7/49 = 14,3%) (group C). In the
second season another seven cases were found in the non-
suspicion group (7/257 = 2,7%) (group E). All NWSs were
also tested for B. parapertussis, but no cases were found in
our study.
The clinical features of the four identified groups in
the second winter are shown in Table 2. Fourteen cases
tested positive for pertussis (group C, (clinical suspicion
RT-PCR positive), and group E (non-suspicion RT-PCR
positive)). All fourteen pertussis patients showed signs of
an URTI, but that symptom was one of the study inclu-
sion criteria. Ten out of these 14 were also diagnosed
with LRTI. All four patients with exclusively URTI fell
into the clinical non-suspicion group. Only one patient
in the non-suspicion group suffered from paroxysmal
cough. Viral co-infections were found in 11 out of 14
cases: in the suspected pertussis group 6 out of 7 had
viral co-infection (1 virus detected n = 6) in the un-
suspected pertussis group 5 cases had viral co-infection
(1 virus detected n = 3; 2 viruses detected n = 2). Influ-
enza A, RSV B, Rhino- and Bocavirus were the most
common pathogens found. All children in the clinical
suspicion group were prescribed claritromycin, in case of
suspected pneumonia amoxicillin was prescribed as well.
Of the pertussis cases, 6/14 were appropriately immu-
nized, 4 were too young to have received completed
immunization and 4 were not immunized based on their
parental beliefs. Of the 14 cases 11 were admitted to the
pediatric ward: 6/7 (86%) in the suspected pertussis group
and 5/7 (71%) in the unsuspected pertussis group.
Multivariate analyses were performed on the groups de-
scribed in analysis 1, 2 and 3. No significant differences
were found between the clinical suspicion RT-PCR po-
sitive group (group A and C) and the clinical suspicion
Table 1 Number of pertussis cases per season
First winter Second winter
Season 2008–2009 (n = 209 ) Season 2009–2010 (n = 373 )
Clinical suspicion of pertussis
Clinical suspicion of pertussis (%) 22/209 (10,5) 49/373 (13,1)
Prospective PCR B, pertussis positive n/N (%) 2/22 (9,1) 7/49 (14,3)
No clinical suspicion of pertussis
No clinical suspicion of pertussis (%) 187/209(89,5) 324/373 (86,9)
Material for retrospective PCR 0/187 (0,0) 257/324 (79,3)
Retrospective PCR B. pertussis positive, n/N (%) NA 7/257 (2,7)
Total number of Pertussis cases, n/N (%) 2/209 (1,0) 14/373 (3,8)
NA: not applicable.
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RT-PCR negative group (group B and D) (Analysis 1: p-
value 0,12).
Among those who tested positive for pertussis in the
second season (group C and E), multivariate analysis
showed significant differences between the suspected
(group C) and the unsuspected pertussis group (group
E) (Analysis 2 p = 0,03). Figure 2 is a visualization of the
differences (in characteristics) between both groups and
Table 2 Features of cases in the second season, divided in four groups
Clinical suspicion Clinical suspicion Non-suspicion Non-suspicion
RT-PCR positive RT-PCR negative RT-PCR positive RT -PCR negative
N = 7 N = 42 N = 7 N = 250
(Figure 1, group C) (Figure 1, group D) (Figure 1, group E) (Figure 1, group F)
Male, n 4 30 1 147
Age, months, mean (range) 14,8 (1,2-49,6) 4,8 (0,1-21,7) 3,8 (0,6 - 8,7) 7,6 (0,1-89,4)
Clinical features
In-hospital cases, n 6 (85,7%) 30 (71,4%) 5 (71,4%) 182 (72,8%)
Fever, n 3 (42,9%) 18 (42,9%) 1 (14,2%) 131 (52,4%)
Coughing, n 7 (100%) 41 (97,6%) 7 (100%) 207 (82,8%)
Rhinorrhea, n 7 (100%) 39 (92,9%) 7 (100%) 231 (92,4%)
Paroxysmal cough, n 6 (85,7%) 25 (59,5) 1 (14,2%) 27 (10,8%)
CRP > 40 mg/L, n 0 (0%) 3 (7,1%) 1 (14,2%) 26 (10,4%)
Oxygen therapy necessary, n 2 (28,6%) 15 (35,7%) 2 (28,6%) 105 (42,0 %)
Nasogastric feeding, n 1 (14,3%) 5 (11,9%) 0 (0,0%) 27 (10,8%)
Wheezing, n 3 (42,9%) 15 (35,7%) 1 (14,2%) 113 (45,2%)
Apnoe, n 0 (0%) 3 (7,1%) 0 (0,0%) 10 (4,0%)
Days of illness, mean (range) 18,3 (5–37) 9,7 (2–42) 10,4 (5–18) 8,3 (1–35)
Disease severity score, mean (range) 9,9 (0–19) 11,7 (0–24) 9,6 (3–18) 13,4 (0–27)
Disease severity score
<6 2 9 2 65
7-13 3 16 3 55
14-19 2 14 2 75
>20 0 3 0 55
Clinical diagnosis
Exclusively URTI 0 23 4 133
Exclusively LRTI 0 0 0 1
Combined URTI/LRTI 7 18 3 106
No URTI or LRTI 0 1 0 10
Pertussis diagnosis
PCR throat swab material, n 4 x 0 x
PCR NWS, n 3 x 7 x
Serology, positive, n 1 x 0 x
Culture, positive n 0 x 0 x
Viral (co)infection
None 1 7 2 37
1 virus 6 21 3 146
≥ 2 virusses 0 14 2 67
Antibiotic therapy
None 0 26 4 158
Amoxicillin, n 1 9 2 94
Claritromycine, n 7 7 1 8
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shows that the two groups can be separated from one
another in space, which means that the two groups differ
in clinical parameters.
To test which factors contributed to the difference be-
tween both groups, a post-hoc test was performed, in
which each factor was analyzed separately (results shown
in Table 3). In the unsuspected pertussis group (group
E) less children had paroxysmal cough (p < 0,01) and less
antibiotics were prescribed (p = 0,01). Location of infec-
tion also significantly differed between the two groups:
more URTIs were found in the unsuspected pertussis
group (p = 0,01) and more combined URTI and LRTI
were found in de clinical suspected group (p = 0,01)
(group C). Other clinical findings (feeding support, pres-
ence of fever) did not differ between the two groups.
Considering that ARI was the main characteristic for in-
clusion, general symptoms belonging to ARI (cough, rhi-
norrhoea) were present in all participants and could
therefore not be included in this post-hoc test. Apnea
was not observed in one of the groups, therefore this
parameter was not included in the post hoc test as well.
No significant differences were found between all RT-
PCR positive cases (group C and E) and all RT-PCR nega-
tive cases (group D and F) (Analysis 3: p-value 0,48).
Since paroxysmal cough is considered one of the main
symptoms of pertussis, we retrospectively assessed the
frequency of paroxysmal cough in ARI. Paroxysmal
cough was reported by the parents or observed by the
clinician. Paroxysmal cough was often seen in children
with ARIs (97/582 = 16,7%). In 43 of 97 cases with par-
oxysmal cough the consulting pediatrician had clinical
suspicion of pertussis and decided to perform diagnos-
tics, 8 out of these 97 were proven pertussis. In 54 of 97
cases with paroxysmal cough the consulting pediatrician
had no clinical suspicion of pertussis. Frequently alterna-
tive diagnoses were noted in the medical chart, mostly
bronchiolitis. Two-thirds of these cases were RSV posi-
tive, some were positive for other viruses. Retrospect-
ively, only one positive pertussis case was found in this
group.
Discussion
In literature, paroxysmal cough is considered the most im-
portant classical symptom of pertussis; it is also a major
criterion in clinical case definitions of de World Health
Organization and Centers for Disease Control and Preven-
tion. Also in the clinical case definitions proposed by the
Global Pertussis Initiative Roundtable Meeting in 2011,
paroxysmal cough is still considered a major criteria in
children above 3 months of age [11]. However this study
shows that clinical suspicion based on paroxysmal cough-
ing only predicts accurately in about 10-15% of cases.
Based on the second study season, theoretically 4 out of 5
pertussis cases were accurately recognized (100 – ((2,7/
14,3) × 100) = 81,1%) and 1 out of 5 pertussis cases was
missed ((2,7/14,3) × 100 = 18,9%) if pertussis diagnostics
are only performed when the doctor has clinical suspicion
of pertussis. In accordance with other reports [4,8,19], we
Figure 2 Visualization of the differences (in characteristics) between the suspected and unsuspected pertussis group.
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observed that paroxysmal cough is not specific for pertus-
sis. In the unsuspected pertussis group less children suf-
fered from paroxysmal cough and more children had only
symptoms of an URTI. This suggests that the current clin-
ical case definitions of pertussis are not sufficient for diag-
nosing all pertussis cases. Especially the atypical and mild
infections, more frequently seen in unvaccinated children,
are missed. Moreover, these children are also at risk for
developing severe life threatening apneas if treatment is
delayed. We showed that paroxysmal cough is also seen in
children with common viral respiratory infections, which
implies that further research should focus on determining
accurate clinical predictors of pertussis.
Our study suggests that reported incidences of pertus-
sis underestimate the true incidences. Our study results
are supported by seroprevalence studies that have shown
that only 20–25% patients with positive serology recall
symptoms during the preceding year [1,20].
Different studies showed that in respiratory infections
often more than one pathogen is found. It is not clear
which pathogen is the primary causative agent and which
associations between pathogens contribute to disease
severity [21]. Also in pertussis, co-infections with re-
spiratory pathogens often occur [9,22]. In our study 11/
14 (78,6%) patients with pertussis had viral co-infections.
Co-infections did not seem to explain the differences found
between the unsuspected and suspected pertussis group.
We could not determine if these infections occurred simul-
taneously or consecutively. Clinical features of cases with
mixed infections do not differ from those with only one or-
ganism present [4,8,22]. In cases of mixed infections, it is
unclear which pathogen contributes most to the disease
symptoms. It is possible that only one organism causes
symptoms while the other micro-organism is only residing
in the respiratory tract. Although some studies [23] suggest
asymptomatic carriage of B. pertussis, situations in which
B. pertussis is detected more likely reflect asymptomatic or
mild infections. The much higher seroprevalence compared
to the number of reported cases supports the idea of
asymptomatic infections or carriage [1]. Additionally, in the
situation of co-infection, coughing due to viral infection
might contribute to transmission of pertussis as well.
The clinical severity of pertussis infections may be
modified by vaccination. Fully vaccinated children are
thought to have more silent or mild pertussis infections
and more severe presentations are seen in unvaccinated
children, especially at a young age [2,5]. In the Netherlands
children are vaccinated against pertussis with an acellular
vaccine at the age of 2, 3, 4 and 11 months and 4 years
[18]. In the study period (2007–2009), overall vaccination
coverage for pertussis in the Netherlands was around 95%
for infants, and 91% for toddlers. In both participating hos-
pitals vaccine coverage was equal to the national percent-
age [18]. In our study 8 out of 14 children with pertussis
were not immunized (yet), from which 4 cases were found
based on clinical suspicion. Of these 8 children, five were
less than two months of age and therefore not (yet) immu-
nized. The other three children were not immunized for
religious reasons. The other six children with pertussis
were immunized with the acellular vaccine, one child was
4 years and fully immunized. The age of the other five var-
ied between 3 and 9 months (mean 6.3 months). Vaccin-
ation strategy and type of vaccination are matter of
interest in literature, duration of immunity might differ be-
tween de whole cell and the acellular vaccines [24]. In our
study, almost all children were vaccinated with the acellu-
lar vaccine, since all children in The Netherlands born
after January 2005 have been vaccinated with this type of
vaccine. De Greeff et al. demonstrated that household con-
tacts play and important role in transmission of pertussis
to children and show that 1–3 years after vaccination chil-
dren are again susceptible for pertussis [6]. It has also been
shown that infection may occur shortly after vaccination,
not always with typical clinical symptoms [3,25] and de-
pending on the efficacy of the vaccine used.
In this study we used RT-PCR to detect B. pertussis,
mostly on NWS/nasopharyngeal aspirates and only a few
times on throat swabs. The method of specimen collection
Table 3 Post-hoc univariate analysis (analysis 2): PCR
Pertussis positive: suspected (group III) versus
non-suspected pertussis group (group V)
Variable P value
Age (months) 0,180a
Gender 0,112b
Coinfections 0,708a
Hospitalization 0,513b
Duration of Illness 0,140a
Fever 0,264b
Cough Np
Rhinorrhea Np
Apnea Np
Wheezing 0,271b
Cyanosis 0,791b
Retractions 0,515b
Tachypnea 0,507b
Paroxysmal coughing 0,0076b
Disease severity score 0,844a
Combined URTI and LRTI 0,0132b
Exclusively URTI 0,0136b
Chest radiograph 0,509b
Start antibiotics 0,0122b
aKruskal Wallis test for continuous variables.
bBinomial test for discrete variables.
np = not possible.
Significant differences noted as bold.
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depended on the experience in the local hospital. NWS/
nasopharyngeal aspirates and throat swabs provide mucus
that contains columnar respiratory epithelial cells, the target
cell for attachment of B. pertussis [2]. In 2005, the Pertussis
Consensus Group recommended NWSs/nasopharyngeal
aspirates as the optimal sample for RT-PCR in infants and
throat swabs as an possible alternative in older children
[26]. In some studies throat swabs are considered subopti-
mal to nasopharyngeal swabs, but Holberg et al. showed
that they have similar sensitivity [27]. In our study, PCR on
throat swabs was done in a minority of cases (11 of which
four tested positive for pertussis). RT-PCR is a rapid, sensi-
tive and specific diagnostic test, may detect infection early
and later in disease progression and may be used in vacci-
nated children, in whom serology is unreliable [2,7]. It is
suggested that RT-PCR for pertussis remains positive at
least three weeks from onset of catarrhal symptoms [2].
After this period, the usefulness of RT-PCR declines and
serology becomes more important in unimmunized chil-
dren [7].
The PCR target used for diagnosis in this study was
IS481, Consequently, we cannot distinguish between
B. pertussis, B. holmesii and B. bronchiseptica. B. holmesii
has been found in three Dutch patients with pertussis-like
symptoms [28] but the prevalence appears to be low [29].
Furthermore, B. holmesii has mainly been found in adoles-
cents and adults [30]. Therefore, we consider it is unlikely
that our data are an overestimation of true data. The use
of the IS481 target instead of species-specific targets in a
clinical setting is further supported by data from a recent
study of Spicer et al. He reported that 222 out of 520
(42.7%) IS481 positive nasopharyngeal specimens were un-
able to be confirmed as having B. pertussis or B. holmesii
by species specific PCR assays. This likely reflects the
greater sensitivity of the IS481 target, because there are
more targets per organism than in an assay using species
specific targets [31].
There are limitations to this study. First, the number of
RT-PCR-positive pertussis samples is small, limiting the
application of the results to the general population. Sec-
ond, serology was not performed. Had serology been in-
cluded, more pertussis cases might have been found.
Another limitation was that no retrospective data on the
first season were available. Also, we cannot exclude some
selection bias in our study, since most children were re-
ferred to the hospital only after initial assessment by a pri-
mary physician, as is common in the Dutch healthcare
system. Therefore, patients with milder disease might be
underrepresented. Furthermore it might be important to
evaluate what makes a physician think whether a patient
has pertussis, considering the fact that our study and other
studies show that paroxysmal cough is not a specific
predictor of pertussis [4,8,19]. Also, the possible dif-
fering interpretations of the definition of paroxysmal
cough between physicians could have led to interpret-
ation bias, with both the risk of over- and underestima-
tion of clinical suspect pertussis cases.
We believe that the results of our study adequately reflect
the situation in national hospitals and most likely also inter-
nationally: in children with respiratory infections, pertussis
diagnostics are not routinely performed, but only in case of
clinical suspicion. The current clinical criteria for pertussis
are all based on paroxysmal cough, which, as we showed, is
not a good predictor in atypical pertussis infections. The
study population of previously healthy children with ARI
are comparable to other pediatric populations. Therefore we
believe our results are also generalizable to similar settings.
Conclusions
Children with pertussis may present with classic or atyp-
ical symptoms. Presentation may mimic a viral respira-
tory tract infection, with the consequence of continuous
spreading of pertussis in the population. Our study
showed that when the initiation of pertussis diagnostics
is based on clinical suspicion, about 1 in 5 cases (19%) is
missed. Despite being widely accepted as a clinical criteria
on pertussis, paroxysmal cough is not a good predictor of
a pertussis infection in our study. In our opinion pertussis
cannot be diagnosed solely on clinical grounds. Therefore,
since pertussis is a treatable disease, we stress the import-
ance of B. pertussis diagnostics, especially in children with
respiratory symptoms. We advocate that if one searches
for a causative pathogen, one should search for treatable
pathogens like B. pertussis. Although more frequent la-
boratory diagnostics may help to limit spread of pertussis
in the population, it comes with high costs. Studies inves-
tigating the cost-effectiveness are warranted.
Appendix
Permanova
PERMANOVA is the non-parametric analogue of the
MANOVA [14]. A permanova can take both continuous
as discrete variables to calculate significant differences
between multiple groups. It does so by testing whether
the similarity of the individuals, based on their charac-
teristics, within a group is smaller than the similarity of
individuals from different groups. In this study Gower
distance was taken a distance measure, since this meas-
ure can handle a mix of datatypes (binary, discrete and
continuous). To test whether the distances within a
group are smaller than between groups a permutation
test was performed, by randomly assigning group labels
1) Clinical suspicion PCR positive (n=9) vs Clinical sus-
picion PCR negative (n=62); 2) Clinical suspicion PCR
positive (n=7) and no clinical suspicion PCR positive
(n=7); and 3) all PCR positive (14 patients) vs. all PCR
negative (292) to each patient. This randomization was
repeated a large number times (999) and gives a null
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distribution of distance values (hypothesis: no differ-
ences between groups). Subsequently, the F test was
used to determine if the observed outcome significantly
differed from the null expectation. The larger the value
of F, the more likely it is that the null hypothesis is
wrong, and that the observed outcome is not likely to
have occurred by chance [14]. Like a MANOVA, a per-
manova is sensitive to differences in variance among
groups, particularly when sample sizes differ substan-
tially. Since we cannot apply a permanova on the full
group sizes, analysis 1 and 3 were performed slightly dif-
ferently. For analysis 1, we randomly took 9 patients
from the group of 62 and compared those with the sus-
pected PCR positive. We then tested for homogeneity of
variances (using the method described by Anderson
[32]) and run the permanova as described above for
group 2. This procedure was repeated 1000 times. The
two groups can be considered significantly different
from each other when more than 950 permanova’s (out of
1000) show a significant difference between the groups
[33]. This procedure was also used for comparing the two
groups in analysis 3. Both analysis 1 and 3 showed no sig-
nificant differences between the groups. Thus there are no
significant differences between the clinical suspicion PCR
positive and clinical suspicion PCR negative group. Also no
differences were found between all PCR positive versus all
PCR negative cases.
Binomial test
Given the significant differences between the clinical sus-
pected and unsuspected group, we subsequently tested
which variables contributed to the differences among the
groups (post-hoc test). For the binary variables, we used a
binomial test. We tested the probability that the frequency
of the symptoms being present in the different groups
could be due to chance. To do so we compared the ratio
of frequencies of a particular symptom in two groups to
the ratio of frequencies of the two groups assuming no dif-
ferences between the two groups (null hypothesis: each
patient, regardless which group it is in, has an equal prob-
ability to show a particular symptom). The frequency
under the null model was generated by drawing 7 and 7
times from a binomial distribution with probability of 0.5.
This was repeated 10,000 times. The thus derived frequency
distribution was compared to the observed frequency. If the
observed frequency falls outside the 95% confidence inter-
val of the null distribution, we consider it unlikely that the
observed frequency distribution is due to chance.
Non metric dimensional scaling (NMDS)
The difference between the patients of the suspected per-
tussis and unsuspected pertussis group was tested using a
PERMANOVA. The test for significant differences in the
PERMANOVA is based on the dissimilarity matrix and
tests whether patients in a group are more similar to each
other (within a group) than between groups. Recall that
the dissimilarity matrix is calculated based on the charac-
teristics of the patients and summarizes how similar pa-
tients are, based on their characteristics, in one number.
Non-metric multidimensional scaling (NMDS) is a way to
visualize these dissimilarities in a chosen number of di-
mensions (in this paper two). The position in two dimen-
sions of the individual patients is shown such that the
rank order of the distance between the patients in the plot
agrees with the dissimilarities of the patients in dissimilar-
ity matrix. The degree to which the rank order distances
agree with the dissimilarities is called “stress”. The lower
the stress the better. The NDMS procedure seeks the or-
dination with lowest stress.
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